Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

The Nucleolus02:55

The Nucleolus

10.5K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
10.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers.

ESMO open·2026
Same author

Effective management of incidental findings in lung cancer screening: the role of the screening review meeting.

Clinical radiology·2025
Same author

Stereotactic Magnetic Resonance-Guided Daily Adaptive SABR (SMART) for Localised Non-Metastatic Pancreatic Cancer: First Reported Clinical Outcomes From the UK.

Clinical oncology (Royal College of Radiologists (Great Britain))·2024
Same author

Lateral Approach to the Cervical Spine to Manage Degenerative Cervical Myelopathy and Radiculopathy.

Acta neurochirurgica. Supplement·2023
Same author

Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.

ESMO open·2022
Same author

Limited utility of plasma elafin as a biomarker for skin graft-versus-host disease following allogeneic stem cell transplantation.

Clinical and experimental dermatology·2021

Related Experiment Video

Updated: Feb 27, 2026

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

8.1K

Targeting nucleolin for better survival in diffuse large B-cell lymphoma.

N Jain1, H Zhu1, T Khashab1,2

  • 1Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Leukemia
|July 11, 2017
PubMed
Summary

Nucleolin is a novel binding partner of topoisomerase-II-alpha (TopIIA) crucial for diffuse large B-cell lymphoma (DLBCL) survival. Targeting nucleolin enhances chemotherapy effectiveness against DLBCL.

More Related Videos

Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells
08:42

Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells

Published on: January 15, 2018

11.7K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.7K

Related Experiment Videos

Last Updated: Feb 27, 2026

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia
09:52

A Chromatin Immunoprecipitation Assay to Identify Novel NFAT2 Target Genes in Chronic Lymphocytic Leukemia

Published on: December 4, 2018

8.1K
Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells
08:42

Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells

Published on: January 15, 2018

11.7K
HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

11.7K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Anthracyclines are vital for treating diffuse large B-cell lymphoma (DLBCL).
  • The efficacy of anthracyclines relies on topoisomerase-II-alpha (TopIIA), a DNA repair enzyme.
  • Nucleolin's role in DLBCL treatment resistance was previously unknown.

Purpose of the Study:

  • To identify novel binding partners of TopIIA.
  • To investigate the role of nucleolin in DLBCL chemoresistance.
  • To explore the therapeutic potential of targeting the nucleolin-TopIIA interaction.

Main Methods:

  • Identified nucleolin as a TopIIA binding partner using biochemical assays.
  • Utilized gene silencing (siRNA) to abrogate nucleolin expression in DLBCL cells.
  • Assessed DNA damage (γH2AX, DNA fragmentation) and apoptosis induction.
  • Mapped the nucleolin-TopIIA binding interface.
  • Tested the efficacy of nucleolin inhibitors (AS1411, N6L) in combination with doxorubicin.

Main Results:

  • Nucleolin directly binds to TopIIA, specifically within RNA-binding domain 3.
  • Abrogation of nucleolin sensitized DLBCL cells to doxorubicin and etoposide, enhancing DNA damage and apoptosis.
  • Nucleolin silencing reduced TopIIA decatenation activity but increased TopIIA-DNA cleavable complex formation.
  • Combined treatment with nucleolin inhibitors and doxorubicin significantly reduced DLBCL cell survival.
  • Low nucleolin levels correlated with poor survival in DLBCL patients treated with R-CHOP therapy.

Conclusions:

  • Nucleolin is a critical mediator of TopIIA function and confers resistance to TopIIA-targeting agents in DLBCL.
  • Targeting the nucleolin-TopIIA interaction represents a promising therapeutic strategy for DLBCL.
  • Nucleolin expression level is a potential prognostic biomarker for DLBCL patients.